Form 4: Verona Pharma CEO David Zaccardelli Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares on November 1st and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- David Zaccardelli, the President and CEO of Verona Pharma plc, sold ordinary shares of the company on November 1, 2024, and November 4, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 8, 2024.
- On November 1, 2024, 46,888 ordinary shares were sold at a weighted average price of $4.3763 per share.
- On November 4, 2024, 94,144 ordinary shares were sold at a weighted average price of $4.3918 per share.
- Following these transactions, Zaccardelli beneficially owns 15,204,752 ordinary shares, including those underlying Restricted Share Units and ADSs.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing share sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by executives are a common occurrence, often planned in advance to avoid accusations of insider trading. The use of a 10b5-1 plan indicates the sales were pre-arranged.
Stakeholder Impact
- Shareholders may react to the news of executive share sales, although the pre-planned nature of the sales may mitigate any negative impact.
- The sales could slightly increase the stock's liquidity.
Key Dates
| Date | Description |
|---|---|
| 03/08/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 11/01/2024 | Date of first transaction: Sale of 46,888 ordinary shares |
| 11/04/2024 | Date of second transaction: Sale of 94,144 ordinary shares |
| 11/05/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.